Supportive care for patients with Guillain-Barré syndrome

Archives of Neurology

Volumn 62, Issue 8, 2005, Pages 1194-1198

  Hughes, Richard A C ^a,j   Wijdicks, Eelco F M ^b   Benson, Estelle ^c   Cornblath, David R ^d   Hahn, Angelika F ^e   Meythaler, Jay M ^f   Sladky, John T ^g   Barohn, Richard J ^h   Stevens, James C ⁱ  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MAYO CLINIC   (United States)

^c Guillain Barre Syndrome Found Intl   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f University of Alabama at Birmingham   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

ⁱ Fort Wayne Neurological Center   (United States)

^j GUY S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ENOXAPARIN; ERYTHROMYCIN; GABAPENTIN; HEPARIN; MORPHINE; NARCOTIC ANALGESIC AGENT; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; TRICYCLIC ANTIDEPRESSANT AGENT;

AIRWAY; ARTIFICIAL VENTILATION; AUTONOMIC DYSFUNCTION; BLADDER CATHETERIZATION; BLADDER DISTENSION; BLADDER DYSFUNCTION; BLOOD PRESSURE MONITORING; BRADYCARDIA; CLINICAL TRIAL; CLOTHING; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG USE; ENTEROPATHY; FATIGUE; GUILLAIN BARRE SYNDROME; HEART ARRHYTHMIA; HEMODYNAMIC MONITORING; HEPARINIZATION; HUMAN; HYPERTENSION; HYPOTENSION; ILEUS; IMMUNIZATION; INTESTINE MOTILITY; KINESIOTHERAPY; MEDLINE; MICTURITION; NEUROPATHIC PAIN; PAIN; PATIENT CARE; POSTOPERATIVE THROMBOSIS; PRESSURE; PRIORITY JOURNAL; PULSE PRESSURE; REHABILITATION MEDICINE; RESPIRATORY FAILURE; RESPIRATORY FUNCTION; REVIEW; THROMBOEMBOLISM; TRACHEOSTOMY; TREATMENT OUTCOME; URODYNAMICS;

AUTONOMIC NERVOUS SYSTEM DISEASES; CONSENSUS; DATABASES, BIBLIOGRAPHIC; FATIGUE; GUILLAIN-BARRE SYNDROME; HUMANS; MONITORING, PHYSIOLOGIC; PAIN; PHYSICAL THERAPY MODALITIES; RESPIRATORY INSUFFICIENCY; VENOUS THROMBOSIS;

EID: 23844468118     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.8.1194     Document Type: Review

References (68)

1. Hughes RAC, Wijdicks E, Barohn RJ, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736-740.
2. Prevots DR, Sutter RW. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis. 1997;175(suppl 1):S151-S155.
3. Raphael JC, Masson C, Morice V, Bronel D, Goulon M. Le syndrome de Guillain-Barré: étude retrospective de 233 observations. Sem Hop Paris. 1984;60:2543-2546.
4. Rees JH, Thompson RD, Smeeton NC, Hughes RAC. An epidemiological study of Guillain-Barré syndrome in South East England. J Neurol Neurosurg Psychiatry. 1998;64:74-77.
5. Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain. 1996;119:2053-2061.
6. Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003;60:1146-1150.
7. Lawn ND, Wijdicks EF. Fatal Guillain-Barré syndrome. Neurology. 1999;52:635-638.
8. Legere BM, Dweik RA, Arroliga AC. Venous thromboembolism in the intensive care unit. Clin Chest Med. 1999;20:367-384.
9. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318:1162-1173.
10. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
11. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg. 1988;208:227-240.
12. Hughes RAC. Guillain-Barré Syndrome. Heidelberg, Germany: Springer-Verlag; 1990.
13. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome. Philadelphia, Pa: FA Davis Co; 1991.
14. Pfeiffer G, Schiller B, Kruse J, Netzer J. Indicators of dysautonomia in severe Guillain-Barré syndrome. J Neurol. 1999;246:1015-1022.
15. Hughes RAC, Bihari D. Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Psychiatry. 1993;56:334-343.
16. Ng KKP, Howard RS, Fish DR, et al. Management and outcome of severe Guillain-Barré syndrome. QJM. 1995;88:243-250.
17. Flachenecker P, Hartung HP, Reiners K. Power spectrum analysis of heart rate variability in Guillain-Barré syndrome: a longitudinal study. Brain. 1997;120:1885-1894.
18. Gracey DR, McMichan JC, Divertie MB, Howard FM Jr. Respiratory failure in Guillain-Barré syndrome: a 6-year experience. Mayo Clin Proc. 1982;57:742-746.
19. Massam M, Jones RS. Ventilatory failure in the Guillain-Barré syndrome. Thorax. 1980;35:557-558.
20. Moore P, James O. Guillain-Barré syndrome: incidence, management, and outcome of major complications. Crit Care Med. 1981;9:549-555.
21. Newton-John H. Prevention of pulmonary complications in severe Guillain-Barré syndrome by early assisted ventilation. Med J Aust. 1985;142:444-445.
22. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EFM. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58:893-898.
23. Ropper AH, Kehne SM. Guillain-Barré syndrome: management of respiratory failure. Neurology. 1985;35:1662-1665.
24. Chevrolet JC, Deleamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis. 1991;144:814-818.
25. Sharshar T, Chevret S, Bourdain F, Raphael JC. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med. 2003;31:278-283.
26. Sunderrajan EV, Davenport J. The Guillain-Barré syndrome: pulmonary-neurologic correlations. Medicine. 1995;64:333-341.
27. Pontoppidan H, Geffin B, Lowenstein E. Acute respiratory failure in the adult, 2. N Engl J Med. 1972;287:743-752.
28. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23:347-353.
29. Henderson RD, Lawn ND, Fletcher MD, McClelland RL, Wijdicks EFM. The morbidity of Guillain-Barré syndrome admitted to the intensive care unit. Neurology. 2003;60:17-21.
30. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997;41:298-306.
31. French Cooperative Group in Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753-761.
32. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 1993;341:586-590.
33. Holdgaard HO, Pedersen J, Jensen RH, et al. Percutaneous dilatational tracheostomy versus conventional surgical tracheostomy: a clinical randomised study. Acta Anaesthesiol Scand. 1998;42:545-550.
34. Dulguerov P, Gysin C, Perneger TV, Chevrolet JC. Percutaneous or surgical tracheostomy: a meta-analysis. Crit Care Med. 1999;27:1617-1625.
35. Griggs WM, Myburgh JA, Worthley LI. A prospective comparison of a percutaneous tracheostomy technique with standard surgical tracheostomy. Intensive Care Med. 1991;17:261-263.
36. Heffner JE. Percutaneous tracheotomy: novel technique or technical novelty? Intensive Care Med. 1991;17:252-253.
37. Lawn ND, Wijdicks EF. Post-intubation pulmonary function test in Guillain-Barré syndrome. Muscle Nerve. 2000;23:613-616.
38. Haymaker W, Kernohan JW. The Landry-Guillain-Barré syndrome: a clinico-pathologic report of fifty fatal cases and a critique of the literature. Medicine (Baltimore). 1949;28:59-141.
39. Marshall J. The Landry-Guillain-Barré syndrome. Brain. 1963;86:55-66.
40. McFarland HR, Heller GL. Guillain-Barré disease complex. Arch Neurol. 1966;14:196-201.
41. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology. 1997;48:328-331.
42. Ravn H. The Landry-Guillain-Barré syndrome: a survey and clinical report of 127 cases. Acta Neurol Scand. 1967;43(suppl 30):1-64.
43. Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy, I: clinical features and their prognostic value. J Neurol Neurosurg Psychiatry. 1988;51:605-612.
44. Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95:1719-1723.
45. Tripathi M, Kaushik S. Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med. 2000;28:655-658.
46. Rosenfeld B, Borel C, Hanley D. Epidural morphine treatment of pain in Guillain-Barré syndrome. Arch Neurol. 1986;43:1194-1196.
47. Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EF. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve. 2001;24:963-965.
48. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve. 1994;17:1145-1155.
49. Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1997;63:649-653.
50. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonie pseudo-obstruction. N Engl J Med. 1999;341:137-141.
51. Meythaler JM. Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil. 1997;78:872-879.
52. Pitetti KH, Barrett PJ, Abbas D. Endurance exercise training in Guillain-Barré syndrome. Arch Phys Med Rehabil. 1993;74:761-765.
53. Herbison GJ, Jaweed M, Ditunno JF. Exercise therapies in peripheral neuropathies. Arch Phys Med Rehabil. 1983;64:201-205.
54. Johnson PC, Fisher CL, Leach C. Hematological implications of hypodynamic states. In: Murray RH, McCally M, eds. Hypogravic and Hypodynamic Environments. Washington, DC: National Aeronautics and Space Administration; 1971:27-34.
55. Meythaler JM, Korkor AB, Kumar NA, Nanda T, Fallon M. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome: successful therapy with combined calcitonin and etidronate. Arch Intern Med. 1986;146:1567-1571.
56. Meythaler JM, DeVivo MJ, Braswell WC. Rehabilitation outcomes of patients who have developed Guillain-Barré syndrome. Am J Phys Med Rehabil. 1997;76:411-419.
57. Bernsen RAJAM, Jacobs HM, De Jager AEJ, van der Meché FGA. Residual health status after Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 1997; 62:637-640.
58. Bernsen RAJAM, De Jager AEJ, Schmitz PIM, van der Meché FGA. Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology. 1999;53:409-410.
59. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA; European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Fatigue in immune-mediated polyneuropathies. Neurology. 1999;53:1648-1654.
60. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121-1123.
61. Karper WB. Effects of low-intensity aerobic exercise on one subject with chronic-relapsing Guillain-Barré syndrome. Rehabil Nurs. 1991;16:96-98.
62. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci. 1985;12:251-254.
63. Garssen MPJ, Schmitz PIM, van der Meché FGA, Merkies ISJ, van Doorn PA. Amantadine for treatment of fatigue after the Guillain-Barré syndrome (GBS), a double-blind, randomized, placebo controlled, cross-overtrial. Neuromuscul Disord. 2002;12:759. Abstract.
64. Wijdicks EFM, Fletcher DD, Lawn DD. Influenza vaccine and the risk of relapse of Guillain-Barré syndrome. Neurology. 2000;55:452-453.
65. Pritchard J, Mukherjee R, Hughes RAC. The risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry. 2002;73:348-349.
66. Seyal M, Ziegler DK, Couch JR. Recurrent Guillain-Barré syndrome following influenza vaccine. Neurology. 1978;28:725-726.
67. Hughes RAC, Choudhary PP, Osborn M, Rees JH, Sanders EACM. Immunisation and risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1996;19:1230-1231.
68. Pollard JD, Selby G. Relapsing neuropathy due to tetanus toxoid. J Neurol Sci. 1978;37:113-125.